Current work and future possibilities for the management of severe influenza: Using immunomodulatory agents that target the host response

Future Virology

Volumn 6, Issue 7, 2011, Pages 843-854

  Alleva, Lisa M ^a   Gualano, Rosa C ^b   Clark, Ian A ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

complementary and alternative medicine; fibrate; glitazone; glycyrrhizin; H1N1 pandemic; H5N1; HMGB1; inflammation; influenza; mitochondria; statin

Indexed keywords

ADENOSINE TRIPHOSPHATE; FLAVONOID; GEMFIBROZIL; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOMODULATING AGENT; MITOCHONDRIAL DNA; PHYTOESTROGEN; PIOGLITAZONE; PLANT EXTRACT; POLYPHENOL; RESVERATROL; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN;

2009 H1N1 INFLUENZA; ALTERNATIVE MEDICINE; APOPTOSIS; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; CELL DEATH; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INFLUENZA; INFLUENZA A (H2N2); MITOCHONDRIAL PERMEABILITY; MITOCHONDRION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79960413119     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.51     Document Type: Review

References (117)

1. Lee N, Wong CK, Chan PK et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin. Infect. Dis. 45(6), 723-731 (2007). (Pubitemid 47378886)
2. Bermejo-Martin JF, Ortiz De Lejarazu R, Pumarola T et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit. Care 13(6), R201 (2009).
3. Cheung CY, Poon LL, Lau AS et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360(9348), 1831-1837 (2002). (Pubitemid 35449422)
4. Tumpey TM, Garcia-Sastre A, Taubenberger JK et al. Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice. J. Virol. 79(23), 14933-14944 (2005). (Pubitemid 41636290)
5. De Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12(10), 1203-1207 (2006). (Pubitemid 44527358)
6. Kobasa D, Jones SM, Shinya K et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445(7125), 319-323 (2007). (Pubitemid 46122819)
7. Perrone LA, Plowden JK, Garcia Sastre A, Katz JM, Tumpey TM. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 4(8), E1000115 (2008).
8. Lee SM, Gardy JL, Cheung CY et al. Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages. PLoS One 4(12), E8072 (2009).
9. Cilloniz C, Shinya K, Peng X et al. Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog. 5, E1000604 (2009).
10. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3. Nature 413, 732-738 (2001). (Pubitemid 33009951)
11. Lund JM, Alexopoulou L, Sato A et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl Acad. Sci. USA 101(15), 5598-5603 (2004). (Pubitemid 38481202)
12. Wang JP, Bowen GN, Padden C et al. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood 112(5), 2028-2034 (2008).
13. Marchant D, Singhera GK, Utokaparch S et al. Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism. J. Virol. 84(21), 11359-11373 (2010).
14. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signalling. Ann. NY Acad. Sci. 1143, 1-20 (2008).
15. Viemann D, Schmolke M, Lueken A et al. H5N1 virus activates signalling pathways in human endothelial cells resulting in a specific imbalanced inflammatory response. J. Immunol. 186, 164-175 (2010).
16. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy - from molecular mechanisms to therapeutic benefits. Biochim. Biophys. Acta 1754, 253-262 (2005). (Pubitemid 41797706)
17. Lee DC, Cheung CY, Law AH, Mok CK, Peiris M, Lau AS. p38 mitogen- activated protein kinase-dependent hyperinduction of tumor necrosis factor a expression in response to avian influenza virus H5N1. J. Virol. 79(16), 10147-10154 (2005). (Pubitemid 41098555)
18. Lawrence T. The nuclear factor NF-kB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1, A001651 (2009).
19. Yarilina A, Park-Min K, Antoniv T, Hu X, Ivashkiv LB. TNF activates an IRF-1- dependent autocrine loop leading to sustained expression of chemokines and STAT1- dependent type I interferon-response genes. Nat. Immunol. 9, 378-387 (2008). (Pubitemid 351405107)
20. Hui KP, Lee SM, Cheung CY et al. Induction of proinflammatory cytokines in primary human macrophages by influenza A virus (H5N1) is selectively regulated by IFN regulatory factor 3 and p38 MAPK. J. Immunol. 182(2), 1088-1098 (2009).
21. Hayden FG, Fritz R, Lobo MC, Alvord W, Strober W, Straus SE. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J. Clin. Invest. 101(3), 643-649 (1998). (Pubitemid 28084248)
22. Morrone G, Ciliberto G, Oliviero S et al. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J. Biol. Chem. 263, 12554-12558 (1988). (Pubitemid 19000437)
23. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi. Viruses 3, 129-142 (2009).
24. Lee SM, Cheung CY, Nicholls JM et al. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J. Infect. Dis. 198(4), 525-535. (2008).
25. Adisasmito W, Chan PK, Lee N et al. Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a Global Patient Registry. J. Infect. Dis. 202, 1154-1160 (2010).
26. Kacergius T, Ambrozaitis A, Deng Y, Gravenstein S. Neuraminidase inhibitors reduce nitric oxide production in influenza virus-infected and g interferon-activated RAW 264.7 macrophages. Pharmacol. Rep. 58(6), 924-930. (2006). (Pubitemid 46117745)
27. Wong ZX, Jones JE, Anderson GP, Gualano RC. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respi. Viruses DOI: 10.1111/j.1750-2659.2011.00235.x (2011) (Epub ahead of print).
28. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51(4), 1414-1424 (2007). (Pubitemid 46586824)
29. Moore ML, Chi MH, Zhou W et al. Cutting Edge. Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity. J. Immunol. 178(5), 2651-2654 (2007). (Pubitemid 46333140)
30. Imai Y, Kuba K, Neely GG et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133(2), 235-249 (2008). (Pubitemid 351512299)
31. Aldridge JR Jr, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl Acad. Sci. USA 106(13), 5306-5311 (2009).
32. Andersson U, Wang H, Palmblad K et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192(4), 565-570. (2000). (Pubitemid 30666257)
33. Fiuza C, Bustin M, Talwar S et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101(7), 2652-2660 (2003). (Pubitemid 36857626)
34. Van Zoelen MAD, Van Der Sluijs K, Achouiti A et al. Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 391, 265-273 (2009).
35. Qin Y-H, Dai S-M, Tang G-S et al. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J. Immunol. 183, 6244-6250 (2009).
36. Bianchi ME. HMGB1 loves company. J. Leukoc. Biol. 86, 573-576 (2009).
37. Alleva LM, Budd AC, Clark IA. Systemic release of high mobility group box 1 protein during severe murine influenza. J. Immunol. 181(2), 1454-1459 (2008).
38. Bonaldi T, Talamo F, Scaffidi P et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22(20), 5551-5560 (2003). (Pubitemid 37279964)
39. Lotfi R, Herzog GI, Demarco RA et al. Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. J. Immunol. 183, 5023-5031 (2009).
40. Bierhaus A, Humpert PM, Stern DM, Arnold B, Nawroth PP. Advanced glycation end product receptor-mediated cellular dysfunction. Ann. NY Acad. Sci. 1043, 676-680 (2005). (Pubitemid 41123959)
41. Branco-Madeira F, Lambrecht BN. High mobility group box-1 recognition: the beginning of a RAGEless era? EMBO Mol. Med. 2, 193-195 (2010).
42. Park JS, Gamboni Robertson F, He Q et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290(3), C917-C924 (2006).
43. Park JS, Svetkauskaite D, He Q et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279(9), 7370-7377 (2004). (Pubitemid 38294612)
44. Tian J, Avalos AM, Mao SY et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8(5), 487-496 (2007). (Pubitemid 46605917)
45. Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial disease: a consequence of inflammatory cytokine release. Malar. J. DOI: 10.1186/1475-2875- 5-85 (2006) (Epub ahead of print).
46. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit. Care Med. 35, S441-S448 (2007). (Pubitemid 47312177)
47. Kim J-S, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem. Biophys. Res. Commun. 304, 463-470 (2003). (Pubitemid 36506518)
48. Zhang Q, Raoof M, Chen Y et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464, 104-107 (2010).
49. Seo YW, Shin JN, Ko KH et al. The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell death. J. Biol. Chem. 278(48), 48292-48299 (2003). (Pubitemid 37523284)
50. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418(6894), 191-195 (2002). (Pubitemid 34773774)
51. Wensveen FM, Van Gisbergen KP, Derks IAM et al. Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high affinity clones. Immunity 32, 754-765 (2010).
52. Yuen KY, Chan PK, Peiris M et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351(9101), 467-471 (1998). (Pubitemid 28070092)
53. Tumpey TM, Lu X, Morken T, Zaki SR, Katz JM. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J. Virol. 74(13), 6105-6116 (2000). (Pubitemid 30412982)
54. Gabriel G, Klingel K, Planz O et al. Spread of infection and lymphocyte depletion in mice depends on polymerase of influenza virus. Am. J. Pathol. 175(3), 1178-1186 (2009).
55. Hussell T, Goulding J. Structured regulation of inflammation during respiratory viral infection. Lancet Infect. Dis. 10, 360-366 (2010).
56. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. Mech. Dis. 3, 279-312 (2008). (Pubitemid 351488283)
57. Dybing JK, Schultz-Cherry S, Swayne DE, Suarez DL, Perdue ML. Distinct pathogenesis of hong kong-origin H5N1 viruses in mice compared to that of other highly pathogenic H5 avian influenza viruses. J. Virol. 74(3), 1443-1450 (2000). (Pubitemid 30044094)
58. Cilloniz C, Pantin-Jackwood MJ, Ni C et al. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J. Virol. 84(15), 7613-7624 (2010).
59. Hitchon CA, Alex P, Erdile LB et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J. Rheumatol. 31, 2336-2346 (2004). (Pubitemid 39603079)
60. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J. Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell. Immunol. 247(2), 72-84 (2007). (Pubitemid 350019447)
61. Verbist KC, Cole CJ, Field MB, Klonowski KD. A role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection. J. Immunol. 186, 174-182 (2010).
62. Arankalle VA, Lole KS, Arya RP et al. Role of host immune response and viral load in the differential outcome of pandemic H1N1 (2009) influenza virus infection in Indian patients. PLoS One 5(10), E13099 (2010).
63. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 405, 421-424 (2000). (Pubitemid 30367411)
64. Smith MR, Standiford TJ, Reddy RC. PPARs in alveolar macrophage biology. PPAR Res. DOI: 10.1155/2007/23812 (2007) (Epub ahead of print). (Pubitemid 350243192)
65. Besson VC, Chen XR, Plotkine M, Marchand-Verrecchia C. Fenofibrate, a peroxisome proliferator-activated receptor a agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci. Lett. 388, 7-12 (2005). (Pubitemid 41569361)
66. Gelosa P, Banfi C, Gianella A et al. Peroxisome proliferator-activated receptor a agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. J. Pharmacol. Exp. Ther. 335, 324-331 (2010).
67. Serghides L, Patel SN, Ayi K et al. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J. Infect. Dis. 199(10), 1536-1545 (2009).
68. Crisafulli C, Cuzzocrea S. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor a (PPAR-a) in the regulation of inflammation in macrophages. Shock 32, 62-73 (2009).
69. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89(6), 2728-2735 (2004).
70. Standiford TJ, Keshamouni VG, Reddy R. Peroxisome proliferator-activated receptor-g as a regulator of lung inflammation. Proc. Am. Thorac. Soc. 2, 226-231 (2005). (Pubitemid 41500850)
71. Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPAR-g activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol. 23, 343-352 (2010).
72. Necela BM, Su WB, Thompson EA. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor g and nuclear factor-kB in macrophages. Immmunology 125, 344-358 (2008).
73. Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents Chemother. 51(8), 2965-2968 (2007). (Pubitemid 47206237)
74. Cabrero A, Laguna JC, Vazquez M. Peroxisome proliferator-activated receptors and the control of inflammation. Curr. Drug Targets Inflamm. Allergy 1(3), 243-248 (2002).
75. Calkin AC, Cooper ME, Jandeleit Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49(4), 766-774 (2006). (Pubitemid 43357552)
76. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin. Infect. Dis. 43(2), 199-205. (2006).
77. Enserink M. Infectious disease. Old drugs losing effectiveness against flu; could statins fill gap? Science 309(5743), 1976-1977 (2005). (Pubitemid 41362292)
78. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect. Dis. 8(9), 571-576 (2008).
79. Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respi. Viruses 4, 307-311 (2010).
80. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect. Dis. 7(5), 358-368 (2007). (Pubitemid 46590065)
81. Morse D, Choi AM. Heme oxygenase-1: the 'emerging' molecule has arrived. Am. J. Respir. Cell. Mol. Biol. 27, 8-16 (2002). (Pubitemid 34657385)
82. Alleva LM, Cai C, Clark IA. Using complementary and alternative medicines to target the host response during severe influenza. Evid. Based Complement. Alternat. Med. 7, 501-510 (2009).
83. Rainsford KD. Influenza ('bird flu'), inflammation and anti-inflammatory/ analgesic drugs. Inflammopharmacology 14(1-2), 2-9 (2006).
84. Wang X, Jia W, Zhao A. Anti-influenza agents from plants and traditional Chinese medicine. Phytother. Res. 20(5), 335-341. (2006).
85. Friel H, Lederman H. A nutritional supplement formula for influenza A (H5N1) infection in humans. Med. Hypotheses 67(3), 578-587 (2006). (Pubitemid 43928312)
86. Fiore C, Eisenhut M, Krausse R et al. Antiviral effects of Glycyrrhiza species. Phytother. Res. 22, 141-148 (2008). (Pubitemid 351363230)
87. Lupfer C, Besnouin D, Tepper SE, Maselko M, Patton KM, Pastey M. Increased survivorship and altered cytokine profile from treatment of influenza A H1N1- infected mice with ekybion: a drug complex of natural extracts and inorganic compounds. Evid. Based Complement. Alternat. Med. DOI: 10.1155/2011/192079 (2011).
88. Michaelis M, Geiler J, Naczk P et al. Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced pro-inflammatory cytokine and chemokine expression in human macrophages. Med. Microbiol. Immunol. 199, 291-297 (2010).
89. Utsunomiya T, Kobayashi M, Pollard RB, Suzuki F. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob. Agents Chemother. 41(3), 551-556. (1997). (Pubitemid 27098402)
90. Palamara AT, Nencioni L, Aquilano K et al. Inhibition of influenza A virus replication by resveratrol. J. Infect. Dis. 191(10), 1719-1729 (2005). (Pubitemid 40656761)
91. Wang JY, Guo JS, Li H, Liu SL, Zern MA. Inhibitory effect of glycyrrhizin on NF-kB binding activity in CCl4- plus ethanol-induced liver cirrhosis in rats. Liver 18(3), 180-185 (1998). (Pubitemid 28368068)
92. Nonn L, Duong D, Peehl DM. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 28(6), 1188-1196 (2006). (Pubitemid 47062677)
93. Lee CS, Kim YJ, Han ES. Glycyrrhizin protection against 3-morpholinosydnonime-indcued mitochondrial dysfunction and cell death in lung epithelial cells. Life Sci. 80, 1759-1767 (2007). (Pubitemid 46527652)
94. Kim DE, Youn YC, Kim YKI, Hong KM, Lee CS. Glycyrrhizin prevents 7-ketocholesterol toxicity against differentiated PC12 cells by suppressing mitochondrial membrane permeability change. Neurochem. Res. 34, 1433-1442 (2009).
95. Mollica L, De Marchis F, Spitaleri A et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 14(4), 431-441. (2007). (Pubitemid 46617319)
96. Kamau E, Takhampunya R, Li T et al. Dengue virus infection promotes translocation of high mobility group box 1 protein from the nucleus to the cytosol in dendritic cells, upregulates cytokine production and modulates virus replication. J. Gen. Virol. 90, 1827-1835 (2009).
97. Huang B, Sikorski R, Kirn DH, Thorne SH. Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Ther. 18(2), 164-172 (2011).
98. Yoke YC, So HT, Abdul Kadir K. Effects of glycyrrhizic acid on peroxisome proliferator-activated receptor g (PPARg), lipoprotein lipase (LPL), serum lipid and HOMA-IR in rats. PPAR Res. 2010, 530265 (2010).
99. Takei H, Baba Y, Hisatsune A et al. Glycyrrhizin inhibits interleukin-8 production and nuclear factor-kB activity in lung epithelial cells, but not through glucocorticoid receptors. J. Pharmacol. Sci. 106(3), 460-468 (2008). (Pubitemid 351468599)
100. Sasaki H, Suzuki N, Al Shwaimi E et al. 18b-glycyrrhetinic acid inhibits perodontitis via glucocorticoid-independent nuclear factor-kB inactivation in interleukin-10- deficient mice. J. Periodont. Res. 45, 757-763 (2010).
101. Yano M, Matsumura T, Senokuchi T et al. Statins activate peroxisome proliferator-activated receptor g through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ. Res. 100(10), 1442-1451 (2007). (Pubitemid 46834756)
102. Haraguchi T, Takasaki K, Naito T et al. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor g-dependent mechanism. Neurosci. Lett. 464, 151-155 (2009).
103. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169(3), 453-459. (2001). (Pubitemid 32536978)
104. Wang K, Zhou Z, Zhang M et al. Peroxisome proliferator-activated receptor g down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model. J. Pharmacol. Exp. Ther. 317, 37-43 (2006).
105. Wang L, Zhang X, Liu L, Yang R, Cui L, Li M. Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kB expression. Neurosci. Lett. 471, 152-156 (2010).
106. Cree MG, Zwetsloot JJ, Herndon DN et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann. Surg. 245(2), 214-221. (2007). (Pubitemid 46148480)
107. Crouser ED. Peroxisome proliferator-activated receptors g coactivator-1a: master regulator of mitochondrial biogenesis and survival during critical illness? Am. J. Respir. Crit. Care Med. 182, 726-728 (2010).
108. Karin M. Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs. Ann. Rheum. Dis. 63(Suppl.), II62-II64 (2004). (Pubitemid 39424660)
109. Yoon JH, Lim T-G, Lee KM, Jeon AJ, Kim SY, Lee KW. Tangeretin reduces ultraviolet (UVB)-induced cyclooxygenase-2 expression in mouse epidermal cells by blocking mitogen-activated protein kinase (MAPK) activation and reactive oxygen species generation. J. Agric. Food Chem. 59(1), 222-228 (2011).
110. Kang OH, Jang HJ, Chae HS et al. Anti-inflammatory mechanisms in activated HMC-1 cells: pivotal roles of NF-kB and MAPK. Pharm. Res 59, 330-337 (2009).
111. Jeng YJ, Watson CS. Proliferative and anti-proliferative effects of dietary levels of phytoestrogens in rat pituitary GH3/B6/F10 cells - the involvement of rapidly activated kinases and caspases. BMC Cancer 9, 334 (2009).
112. Francisco V, Figueirinha A, Neves BM et al. Cymbopogon citratus as a source of new and safe anti-inflammatory drugs: bio-guided assay using lipopolysaccharide-stimulated macrophages. J. Ethnopharmacol. 133(2), 818-827 (2011).
113. Miwatashi S, Arikawa Y, Kotani E et al. Novel inhibitor of p38 MAP kinase as an anti- TNF-a drug: discovery of N-[4-[2-ethyl-4- (3-methylphenyl)-1,3- thiazol-5-yl]-2-pyridyl] benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J. Med. Chem. 48, 5966-5979 (2005). (Pubitemid 41324607)
114. Thompson AJV, Locarnini S. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol. Cell Biol. 85, 435-445 (2007). (Pubitemid 47367510)
115. Ichinohe T. Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design. Expert Rev. Vaccines 9(11), 1315-1324 (2010).
116. Le Goffic R, Pothlichet J, Vitour D et al. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J. Immunol. 178(6), 3368-3372 (2007). (Pubitemid 46417600)
117. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat. Immunol. 11(5), 404-410 (2010).